Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma, summarised by Arndt Vogel
Arndt Vogel, Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X:
“Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different PD-L1 subgroups.
– only very modest benefit in PD-L1 low HER-2 negative GEAC
– Zolbetuximab better alternative in Claudin18.2+ tumors.”
Authors: A.G. Leone, A.S. Mai, K.Y. Fong, D.W.T. Yap, K. Kato, E. Smyth, M. Moehler, J.T.C. Seong, R. Sundar, J
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023